TMPRSS2 and prostate adenocarcinoma: Mutation analysis of the pan-cancers revealed that the TMPRSS2 mutation frequency was significantly higher in PRAD and that the mutated TMPRSS2 group was significantly associated with long overall, progression-free, disease-specific, and disease-free survival compared to the WT TMPRSS2 group, demonstrating a loss of function roles for TMPRSS2 mutations as prognostic markers in pan-cancers.